Sparsentan (Filspari) becomes first approved treatment for focal segmental glomerulosclerosis

1. Sparsentan (Filspari) becomes the first approved treatment specifically for focal segmental glomerulosclerosis. 2. Clinical trial data show meaningful reductions in proteinuria, a key marker of disease progression. The FDA granted full approval to sparsentan (Filspari) on April 13, 2026, for the reduction of proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis.…